Loading company…
Riskpilot
← Back to search
Sign in
Get full access
PRIMEBIO HOLDING AS
AS
Active
Org 828098632
Gjellestadveien 8B, 1813 Askim
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2021
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
NOK 0
EBITDA margin
—
-81500% vs 2023
Equity ratio
100.0%
Financial strength
Net profit 2024
NOK -5K
-81500% vs 2023
EBITDA — year on year
NOK millions
0M
-0M
-1M
-1M
-1M
0M
2022
0M
0%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
NOK 0
—
EBITDA
NOK -5K
-81500%
Net profit
NOK -5K
-81500%
Total assets
NOK 19K
-36%
Equity
NOK 19K
-36%
Employees
0
—
Company information
Legal name
PRIMEBIO HOLDING AS
Org number
828098632
Legal form
Aksjeselskap
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
9. november 2021
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Company purpose
Hovedkontortjenester.
Contact
Address
Gjellestadveien 8B, 1813 Askim
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Indre Østfold
All Norway companies
Revenue
NOK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
EBITDA
NOK millions
0M
0M
1M
1M
1M
0M
2022
0M
2023
0M
2024
Income statement
NOK thousands
Item
2022
2023
2024
Revenue
0
0
0
Staff expenses
−0
−0
−0
EBITDA
0
−0
−5
Depreciation & amort.
−0
−0
−0
EBIT
0
−0
−5
Net financials
0
0
0
Profit before tax
0
−0
−5
Tax
−0
−0
−0
Net profit
0
−0
−5
Balance sheet
NOK thousands
Item
2022
2023
2024
Total assets
30
30
19
Equity
30
30
19
Long-term debt
0
0
0
Short-term debt
0
0
0
Total debt
0
0
0
Financial ratios
5-year trend
EBITDA margin
-489600.0%
This company
15.8%
Market median
-3098834% vs market
2022
2024
Equity ratio
100.0%
This company
38.2%
Market median
+162% vs market
2022
2024
Return on equity
-25.6%
This company
18.4%
Market median
-239% vs market
2022
2024
Net profit margin
-489600.0%
This company
8.1%
Market median
-6044544% vs market
2022
2024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
2022
2024
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
2022
2024
Annual reports & filings
Annual report 2024
Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
View
PDF
Management
Actively employed in the business
Name
Role
Member since
Current (2)
HH
Hannah Huahong Wang
Chief Executive Officer
Chief Executive Officer
2021
HW
Huahong Wang
Chief Executive Officer
Chief Executive Officer
2021
Board of directors
Non-executive oversight
Name
Role
Member since
Current (1)
YG
Yanwu Guo
Chairman
2021
Shareholders
As of last annual report
Shareholder
Type
Ownership
Votes
Since
Angenovo As
Company
100%
100%
2023
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
Angenovo As
PRIMEBIO HOLDING AS
(this company)
Board network connections
Board members of PRIMEBIO HOLDING AS also hold positions in
0
other companies.
Person
Role here
Other companies
Hannah Huahong Wang
Chief Executive Officer
0 companies
Huahong Wang
Chief Executive Officer
0 companies
Yanwu Guo
Chairman
0 companies